AMINOCAPROIC ACID

Post-LOE

aminocaproic acid

KalVista Pharmaceuticals

ANDAORALTABLET

Approved

Nov 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMINOCAPROIC ACID (aminocaproic acid) by KalVista Pharmaceuticals is clinical pharmacology the fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Approved for anemia. First approved in 2019.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2…

Pharmacologic Class:

Antifibrinolytic Agent

Indications (1)

anemia

Worked on AMINOCAPROIC ACID at KalVista Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.